Benzamide, 4-[(1S,2S)-2-[(4-cyclobutyl-1-piperazinyl)carbonyl]cyclopropyl]- manufacturers
- AZD5213
-
- $2800.00
-
2026-05-21
- CAS:1119807-02-1
- Purity:
- Supply Ability: 10g
|
| | Benzamide, 4-[(1S,2S)-2-[(4-cyclobutyl-1-piperazinyl)carbonyl]cyclopropyl]- Basic information |
| | Benzamide, 4-[(1S,2S)-2-[(4-cyclobutyl-1-piperazinyl)carbonyl]cyclopropyl]- Chemical Properties |
| Boiling point | 547.6±50.0 °C(Predicted) | | density | 1.275±0.06 g/cm3(Predicted) | | pka | 16.19±0.50(Predicted) |
| | Benzamide, 4-[(1S,2S)-2-[(4-cyclobutyl-1-piperazinyl)carbonyl]cyclopropyl]- Usage And Synthesis |
| Uses | AZD5213 is a selective and competitive human H3 receptor antagonist with a pKi value of 9.3 for hH3R. AZD5213 can be used for the research of sleep and cognitive regulation[1][2]. | | in vivo | AZD5213 (1 mg/kg; i.v., once) rapidly reduces of [11C] 4-(1S,2S)-2-(4-cyclobutylpiperazine-1-carbonyl)-cyclopropyl]-N-methyl-benzamide binding in all brain regions of mice[1]. | | References | [1] Schou M, et al. Discovery and Preclinical Validation of [(11)C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor. ACS Chem Neurosci. 2016 Feb 17;7(2):177-84. DOI:10.1021/acschemneuro.5b00268
[2] Nikolic K, et al. Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities. CNS Neurosci Ther. 2014 Jul;20(7):613-23. DOI:10.1111/cns.12279 |
| | Benzamide, 4-[(1S,2S)-2-[(4-cyclobutyl-1-piperazinyl)carbonyl]cyclopropyl]- Preparation Products And Raw materials |
|